BWXT Awarded Contract to Develop Pilot Plant Solution for Domestic Uranium Enrichment

(LYNCHBURG, Va. – August 26, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced a contract from the National Nuclear Security Administration (NNSA) to complete a yearlong engineering study to evaluate options for the deployment of a centrifuge pilot plant that would establish a domestic uranium enrichment capability for national security purposes. Awarded to BWXT […]

BWXT Names Vittorio Puppo President of Medical Business

KANATA, Ontario– BWX Technologies, Inc. (NYSE: BWXT) has appointed Vittorio Puppo as president of BWXT Medical Ltd., effective August 12, 2024. In his new role, Puppo will focus on advancing the business’ mission to deliver high-quality nuclear medical products and solutions that improve patient outcomes worldwide. Puppo brings a wealth of experience to BWXT Medical, […]

BWX Technologies Reports Second Quarter 2024 Results

LYNCHBURG, Va.–(BUSINESS WIRE)–BWX Technologies, Inc. (NYSE: BWXT) (“BWXT”, “we”, “us” or the “Company”) reported second quarter 2024 results. A reconciliation of non-GAAP results are detailed in Exhibit 1. “In recent months there have been multiple important developments supporting our nuclear markets, including passage of the ADVANCE Act, federal and state legislation supporting small modular reactor […]

BWXT to Evaluate Locations for Building New Nuclear TRISO Fuel Production Facility to Support Advanced Reactor Deployment

BWXT and Wyoming Energy Authority Sign Cooperation Agreement to Examine Potential Construction Options in the State (LYNCHBURG, Va. – July 18, 2024) – BWX Technologies, Inc. (NYSE: BWXT) is evaluating locations for a potential new TRISO nuclear fuel production facility to support anticipated future demand for advanced reactor deployment. As part of this effort, BWXT’s […]

BWXT Awarded Phase Two of Microreactor Evaluation Contract for State of Wyoming

(LYNCHBURG, Va. – June 17, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced the award of the second phase of a contract with the Wyoming Energy Authority to assess the viability of deploying small-scale nuclear reactors in the state as a source of resilient and reliable energy to augment existing power generation resources. Under […]

BWXT Medical Submits Drug Master File for Actinium-225 API to U.S. Food and Drug Administration

(OTTAWA, Ontario – June 7, 2024) – BWXT Medical Ltd. has submitted a Drug Master File (DMF) to the U.S. Drug and Food Administration (FDA) for No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient. Ac-225 is an alpha-emitting isotope used in targeted alpha therapies (TATs) that combine the isotope with specific tumor-seeking targeting vectors […]

BWXT employees trained as Nuclear Ambassadors

BWX Technologies, Inc. (BWXT) has partnered with the American Nuclear Society to offer customized ANS Nuclear Ambassadors training to BWXT employees. The training kicked off in February with an initial two-hour virtual event that was presented to more than 60 BWXT employees, and it wrapped in April. BWXT is the first company to participate in ANS’s newly […]

BWX Technologies Reports First Quarter 2024 Results

Lynchburg, VA – May 6, 2024 – BWX Technologies, Inc. (NYSE: BWXT) (“BWXT”, “we”, “us” or the “Company”) reported first quarter 2024 results. A reconciliation of non-GAAP results are detailed in Exhibit 1. “We started 2024 with solid operating results in each of our business segments, both financially and strategically,” said Rex. D. Geveden, president and chief executive […]

This Website Uses Cookies.

We use cookies to give you the best user experience. No personal information is collected in this process.